Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2019’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy

– The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects

– The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

Apexian Pharmaceuticals Inc

Aphios Corp

Aptinyx Inc

Asahi Kasei Pharma Corp

Celgene Corp

DermaXon LLC

Disarm Therapeutics Inc

Emerald Bioscience Inc

Exodos Life Sciences Limited Partnership

Immune Pharmaceuticals Inc

Insys Therapeutics Inc

KannaLife Sciences Inc

Kineta Inc

Kyorin Pharmaceutical Co Ltd

MAKScientific LLC

Metys Pharmaceuticals AG

Mundipharma International Ltd

NeurExo Sciences LLC

Osmol Therapeutucs Inc

PeriphaGen Inc

PharmatrophiX Inc

PledPharma AB

Sensei Biotherapeutics Inc

Sonnet BioTherapeutics Inc

Sova Pharmaceuticals Inc

Stealth BioTherapeutics Corp

Trevena Inc

WEX Pharmaceuticals Inc

Winsantor Inc

YD Life Science Co

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Peripheral Neuropathy - Overview

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Apexian Pharmaceuticals Inc

Aphios Corp

Aptinyx Inc

Asahi Kasei Pharma Corp

Celgene Corp

DermaXon LLC

Disarm Therapeutics Inc

Emerald Bioscience Inc

Exodos Life Sciences Limited Partnership

Immune Pharmaceuticals Inc

Insys Therapeutics Inc

KannaLife Sciences Inc

Kineta Inc

Kyorin Pharmaceutical Co Ltd

MAKScientific LLC

Metys Pharmaceuticals AG

Mundipharma International Ltd

NeurExo Sciences LLC

Osmol Therapeutucs Inc

PeriphaGen Inc

PharmatrophiX Inc

PledPharma AB

Sensei Biotherapeutics Inc

Sonnet BioTherapeutics Inc

Sova Pharmaceuticals Inc

Stealth BioTherapeutics Corp

Trevena Inc

WEX Pharmaceuticals Inc

Winsantor Inc

YD Life Science Co

Chemotherapy Induced Peripheral Neuropathy - Drug Profiles

(amitriptyline + ketamine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACY-1083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-1710 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APH-1503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-2009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-3330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atexakin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Chemotherapy Induced Peripheral Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BR-297 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Chemotherapy Induced Peripheral Neuropathy and Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DX-0332 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCP-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLS-13019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-11A31BHS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRX-2922 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAN-811 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGN-503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirenzepine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-095 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ricolinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Nav

1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SARM1 for Neurology and Glaucoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SV-250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tetrodotoxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thrombomodulin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRV-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YD-308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products

Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones

Featured News & Press Releases

Oct 22, 2019: Disarm Therapeutics reports preclinical data demonstrating small molecule SARM1 inhibitors preserve both axonal structure and function in vitro and in vivo

Sep 04, 2019: Disarm Therapeutics announces first subject enrolled in EPIPHANY natural history study of chemotherapy-induced peripheral neuropathy (CIPN)

Jun 27, 2019: Kannalife to present breakthrough CIPN study findings on the comparison of KLS-13019 to CBD at 29th Annual International Cannabinoid Research Society Conference

May 21, 2019: Kannalife publishes new research on chemotherapy-induced peripheral neuropathy

Jan 17, 2019: PledPharma presents PledOx's phase III program at the Gastrointestinal (GI) Cancers Symposium

Dec 26, 2018: Solasia initiates phase III program for PledOx in Japan

Sep 28, 2018: Study drug for the PledOx global phase III program delivered

Jun 13, 2018: Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx to include Japanese patients

Apr 16, 2018: Apexian Pharmaceuticals to present two poster sessions at AACR meeting in Chicago - April 14-18, 2018

Feb 08, 2018: Delayed delivery of study drug for the PledOx phase III program - top-line results still expected during 2020, in line with previous communication

Nov 17, 2017: PledPharma’s Phase IIb study with PledOx (PLIANT) published in Acta Oncologica

Nov 16, 2017: PledPharma initiates Phase III studies with PledOx before year end 2017

Sep 27, 2017: National Cancer Institute selects Apexian Pharmaceuticals to participate in the Small Business Innovation Research (SBIR) Initiative program

Aug 24, 2017: PledPharma establishes a Scientific Advisory Board for the continued clinical development of PledOx

Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Table 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Universities/Institutes, H2 2019

Table 5: Products under Development by Companies, H2 2019

Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 7: Products under Development by Universities/Institutes, H2 2019

Table 8: Number of Products by Stage and Target, H2 2019

Table 9: Number of Products by Stage and Mechanism of Action, H2 2019

Table 10: Number of Products by Stage and Route of Administration, H2 2019

Table 11: Number of Products by Stage and Molecule Type, H2 2019

Table 12: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Achelios Therapeutics Inc, H2 2019

Table 13: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Apexian Pharmaceuticals Inc, H2 2019

Table 14: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Aphios Corp, H2 2019

Table 15: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Aptinyx Inc, H2 2019

Table 16: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Asahi Kasei Pharma Corp, H2 2019

Table 17: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Celgene Corp, H2 2019

Table 18: Chemotherapy Induced Peripheral Neuropathy – Pipeline by DermaXon LLC, H2 2019

Table 19: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Disarm Therapeutics Inc, H2 2019

Table 20: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Emerald Bioscience Inc, H2 2019

Table 21: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Exodos Life Sciences Limited Partnership, H2 2019

Table 22: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Immune Pharmaceuticals Inc, H2 2019

Table 23: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Insys Therapeutics Inc, H2 2019

Table 24: Chemotherapy Induced Peripheral Neuropathy – Pipeline by KannaLife Sciences Inc, H2 2019

Table 25: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Kineta Inc, H2 2019

Table 26: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019

Table 27: Chemotherapy Induced Peripheral Neuropathy – Pipeline by MAKScientific LLC, H2 2019

Table 28: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Metys Pharmaceuticals AG, H2 2019

Table 29: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Mundipharma International Ltd, H2 2019

Table 30: Chemotherapy Induced Peripheral Neuropathy – Pipeline by NeurExo Sciences LLC, H2 2019

Table 31: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Osmol Therapeutucs Inc, H2 2019

Table 32: Chemotherapy Induced Peripheral Neuropathy – Pipeline by PeriphaGen Inc, H2 2019

Table 33: Chemotherapy Induced Peripheral Neuropathy – Pipeline by PharmatrophiX Inc, H2 2019

Table 34: Chemotherapy Induced Peripheral Neuropathy – Pipeline by PledPharma AB, H2 2019

Table 35: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Sensei Biotherapeutics Inc, H2 2019

Table 36: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Sonnet BioTherapeutics Inc, H2 2019

Table 37: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Sova Pharmaceuticals Inc, H2 2019

Table 38: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Stealth BioTherapeutics Corp, H2 2019

Table 39: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Trevena Inc, H2 2019

Table 40: Chemotherapy Induced Peripheral Neuropathy – Pipeline by WEX Pharmaceuticals Inc, H2 2019

Table 41: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Winsantor Inc, H2 2019

Table 42: Chemotherapy Induced Peripheral Neuropathy – Pipeline by YD Life Science Co, H2 2019

Table 43: Chemotherapy Induced Peripheral Neuropathy – Dormant Projects, H2 2019

Table 44: Chemotherapy Induced Peripheral Neuropathy – Dormant Projects, H2 2019 (Contd..1), H2 2019

Table 45: Chemotherapy Induced Peripheral Neuropathy – Discontinued Products, H2 2019

List of Figures

List of Figures

Figure 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports